Marshall Wace LLP Acquires 256,967 Shares of Vincerx Pharma, Inc. (NASDAQ:VINC)

Marshall Wace LLP raised its position in Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 328,533 shares of the company’s stock after buying an additional 256,967 shares during the quarter. Marshall Wace LLP owned 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent reporting period.

Separately, Vanguard Group Inc. grew its holdings in shares of Vincerx Pharma by 29.9% during the 1st quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock worth $3,375,000 after purchasing an additional 153,575 shares in the last quarter. 44.02% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Leerink Partners reduced their price objective on Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Tuesday.

Vincerx Pharma Stock Performance

Vincerx Pharma stock opened at $0.39 on Friday. Vincerx Pharma, Inc. has a 12 month low of $0.38 and a 12 month high of $9.37. The company has a market capitalization of $11.63 million, a PE ratio of -0.30 and a beta of 1.49. The stock has a 50-day moving average price of $0.67 and a two-hundred day moving average price of $1.06.

Vincerx Pharma (NASDAQ:VINC) last issued its earnings results on Thursday, August 8th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.12. As a group, analysts predict that Vincerx Pharma, Inc. will post -0.38 earnings per share for the current fiscal year.

Vincerx Pharma Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.